BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 10555993)

  • 1. Effect of graft-versus-host disease (GVHD) on host hematopoietic progenitor cells is mediated by Fas-Fas ligand interactions but this does not explain the effect of GVHD on donor cells.
    Iwasaki T; Hamano T; Saheki K; Kuroiwa T; Kataoka Y; Takemoto Y; Ogata A; Sugihara A; Terada N; Fujimoto J; Kakishita E
    Cell Immunol; 1999 Oct; 197(1):30-8. PubMed ID: 10555993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graft-versus-host-disease-associated donor cell engraftment in an F1 hybrid model is dependent upon the Fas pathway.
    Iwasaki T; Hamano T; Saheki K; Kuroiwa T; Kataoka Y; Takemoto Y; Ogata A; Fujimoto J; Kakishita E
    Immunology; 2000 Jan; 99(1):94-100. PubMed ID: 10651946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
    Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
    J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis.
    Pearl-Yafe M; Yolcu ES; Stein J; Kaplan O; Shirwan H; Yaniv I; Askenasy N
    Exp Hematol; 2007 Oct; 35(10):1601-12. PubMed ID: 17889725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fas ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and nonimmunogenic interactions.
    Pearl-Yafe M; Yolcu ES; Stein J; Kaplan O; Yaniv I; Shirwan H; Askenasy N
    Stem Cells; 2007 Jun; 25(6):1448-55. PubMed ID: 17363551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mice deficient in fas ligand (gld) or fas (lpr) show few alterations in granulopoiesis.
    Fecho K; Bentley SA; Cohen PL
    Cell Immunol; 1998 Aug; 188(1):19-32. PubMed ID: 9743554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect.
    Imado T; Iwasaki T; Kuroiwa T; Sano H; Hara H
    Transplantation; 2004 Feb; 77(3):391-8. PubMed ID: 14966413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulation of Fas and the costimulatory molecules B7-1 and B7-2 on peripheral lymphocytes in autoimmune B6/gld mice.
    Weintraub JP; Eisenberg RA; Cohen PL
    J Immunol; 1997 Oct; 159(8):4117-26. PubMed ID: 9379003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A major role for the Fas pathway in acute graft-versus-host disease.
    Via CS; Nguyen P; Shustov A; Drappa J; Elkon KB
    J Immunol; 1996 Dec; 157(12):5387-93. PubMed ID: 8955186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of Fas-mediated apoptosis in the hematopoietic progenitor cells of graft-versus-host reaction-associated myelosuppression.
    Mori T; Nishimura T; Ikeda Y; Hotta T; Yagita H; Ando K
    Blood; 1998 Jul; 92(1):101-7. PubMed ID: 9639505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas cross-linking mimics the inhibitory effect of anti-CD3 on IL-3-induced histamine and cytokine production by murine myeloid spleen cell precursors.
    Ben Amor A; Schneider E; Arnould A; Machavoine F; Dy M
    Exp Hematol; 1998 Aug; 26(9):903-9. PubMed ID: 9694512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Selected elimination of mouse alloreactive T cells by Fas-FasL passway].
    Liu L; Zou P; Xu Z; Hu Z; Chen Y; Song S
    Zhonghua Xue Ye Xue Za Zhi; 2002 Apr; 23(4):187-90. PubMed ID: 12133454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect on the proliferation and apoptosis of alloreactive T cells of cell dose in a murine MHC-mismatched hematopoietic cell transplantation model.
    Fujioka T; Taniguchi Y; Masuda T; Nishida S; Ikegame K; Kawakami M; Tsuboi A; Hosen N; Murakami M; Oji Y; Oka Y; Sugiyama H; Kawase I; Ogawa H
    Transpl Immunol; 2003; 11(2):187-95. PubMed ID: 12799203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fas-mediated liver damage in MRL hemopoietic chimeras undergoing lpr-mediated graft-versus-host disease.
    Bobé P; Bonardelle D; Reynès M; Godeau F; Mahiou J; Joulin V; Kiger N
    J Immunol; 1997 Nov; 159(9):4197-204. PubMed ID: 9379013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
    Li Y; Guo K; Chen Y; Song Z; Li J; Deng L
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):411-4. PubMed ID: 12411044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory arthropathy in MRL hematopoietic chimeras undergoing Fas mediated graft-versus-host syndrome.
    Bonardelle D; Bobé P; Reynès M; Amouroux J; Tricottet V; Godeau F; Kiger N
    J Rheumatol; 2001 May; 28(5):956-61. PubMed ID: 11361222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term myeloid reconstitution following TBI is not adversely affected by doses of FK506 that abrogate lethal GVHD.
    Cooper MH; Patrene KD; Vecchini F; Austin CA; Markus PM; Boggs SS
    Bone Marrow Transplant; 1994 Sep; 14(3):355-62. PubMed ID: 7527689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A metalloproteinase inhibitor prevents acute graft-versus-host disease in mice after bone marrow transplantation.
    Hattori K; Hirano T; Ushiyama C; Miyajima H; Yamakawa N; Ikeda S; Yoshino K; Tateno M; Oshimi K; Kayagaki N; Yagita H; Okumura K
    Bone Marrow Transplant; 1999 Jun; 23(12):1283-9. PubMed ID: 10414917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease.
    Georgantas RW; Bohana-Kashtan O; Civin CI
    Transplantation; 2006 Aug; 82(4):471-8. PubMed ID: 16926590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.